ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Other Events

Item 8.01Other Events.

Nasdaq Compliance

On February 21, 2017, EnteroMedics Inc. (the Company) issued a
press release announcing that the Company received a letter on
February 17, 2017 from the Listing Qualifications Staff (the
Staff) of The NASDAQ Stock Market LLC (Nasdaq) stating that the
Staff had determined that the Company was again in compliance
with Nasdaq Listing Rule 5550(b) (the Rule) after the closing of
the Companys underwritten public offering of units for gross
proceeds of $19.0 million on January 23, 2017.The letter further
stated that the Company has evidenced compliance with all
requirements for continued listing on The Nasdaq Capital Market
and the matter is now closed.The Company had previously disclosed
on a Current Report on Form 8-K filed on May 13, 2016 that the
Company was not in compliance with the Rule because it did not
have stockholders equity of at least $2.5 million.

As previously disclosed on a Current Report on Form 8-K filed on
January 31, 2017, the Company attended a hearing before a Nasdaq
Listing Qualifications Panel (the Panel) on January 12, 2017
related to the Companys previously reported non-compliance with
the Rule and Nasdaqs $1.00 per share bid price requirements. On
January 30, 2017, the Panel issued a decision deeming the Company
in compliance with the $1.00 per share bid price requirement and
requiring the Company to make a filing demonstrating its return
to compliance with the minimum shareholders equity requirement
following the closing of the underwritten public offering
referenced above. As required by the Panel, the Current Report on
Form 8-K filed on January 31, 2017 stated that the Company was
again in compliance with the Rule.

A copy of the press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.

Earnings Release Conference Call

to the press release issued on February 21, 2017, the Company
announced that it will host a conference call on Tuesday, March
7, 2017 at 11:00 AM Eastern Time to discuss financial results for
the fourth quarter ended December 31, 2016 and to provide an
update on the commercialization of the Company’s vBloc
Neurometabolic Therapy.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

About ENTEROMEDICS INC. (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

ENTEROMEDICS INC. (NASDAQ:ETRM) Recent Trading Information

ENTEROMEDICS INC. (NASDAQ:ETRM) closed its last trading session down -0.51 at 6.64 with 587,183 shares trading hands.